PCT Ltd enters into Master Services Agreement for Installation of Annihilyzer® Infection Control Systems in the Greater New York Area

PCT Ltd (OTCPink:PCTL)

LITTLE RIVER, S.C., Oct. 26, 2018 (GLOBE NEWSWIRE) -- PCT LTD’s operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp), announced today it has entered into a Master Services Agreement with a New York-based hospital supply and services company for the installation of two Annihilyzer^® Infection Control Systems to prevent hospital-acquired infections (HAI’s) in hospitals in its market area.  

According to the Center for Disease Control & Prevention (CDC), “On any given day, about one in 25 hospital patients has at least one healthcare-associated infection.” Quoted in , Lynn White, MD, president of Patient Shield Concepts, said “…the estimated direct medical cost of HAIs is around $10 billion annually, not including cost-shifting to private payers. Including cost-shifting, HAIs may cost closer to between $35 billion and $45 billion for acute-care hospitals annually. The total direct, indirect and nonmedical social costs of HAIs are estimated at around $96 billion to $147 billion annually, including loss of work, legal costs and other patient factors.”

The Annihilyzer^® Infection Control System produces on-site generated Electrochemically Activated cleaner and disinfectant fluid solutions that allow hospitals to move away from traditional disinfectants that are toxic and can cause harm to the housekeeping staff and patients to a cleaner and a disinfectant that are safe, environmentally sound and greatly reduce the damage to furnishings and equipment caused by toxic chemicals, yet is effective against HAI’s like MRSA, VRE and C-diff. PCT Health’s system tracks the life cycle of the cleaner and disinfectant and alerts the user before the product is no longer at its optimum effectiveness.

The tracking system can be customized to track employees to ensure that all proper cleaning and disinfecting protocols are being performed during the cleaning process. This assists the hospital administration by supplying valuable data regarding the who, what, when and how all areas of the hospital are cleaned and disinfected.

This system also incorporates the use of Electrostatic Smart Applicators that apply disinfectant to all surfaces. Human error associated with improper application and coverage of disinfectant is no longer an issue as the electrostatic applicators ensure that all surfaces are covered and wrapped with disinfectant. Fogging or misting systems are not time or cost effective whereas the electrostatic application process is more thorough and takes less time, so room turnover is much faster. The Annihilyzer^® Infection Control System is very cost effective and performs well where other cleaning and disinfecting systems sometimes fail.

For additional information about the Annihilyzer^® Infection Control System, visit

About PCT:

PCT LTD (“PCTL”) focuses its business on acquiring, developing and providing sustainable, environmentally safe disinfecting and tracking technologies products. The company acquires and holds rights to innovative products and technologies, which are commercialized through its wholly-owned operating subsidiary, Paradigm Convergence Technologies Corporation (PCT Corp). Currently trading on OTC, “PCTL” aspires to and is actively engaged in preparations for up-listing to a national securities exchange. The Company established entry into its target markets with commercially-viable products and now prepares to gain market share.

PCT Corp's business mission is to profitably provide state-of-the-art Electro-Chemical Activation equipment, disinfecting fluid solutions and PCT Corp's patented tracking system to hospitals and other facilities for the documentable remediation of Hospital Acquired Infections (HAI's) from organisms such as Clostridium difficile (C. diff.), MRSA, VRE, CRE, Klebsiella pneumoniae, and Pseudomonas, as well as to sell ECA fluid solutions to agricultural markets for the remediation, control and suppression of microbial contamination and disease of certain commercial crops. The Company's primary fluid solution, branded Hydrolyte^®, is an EPA registered "hospital-level" disinfectant effective against common healthcare pathogens such as Tuberculosis (TB), HIV-1, Hepatitis C, Norovirus, Rhinovirus, Influenza A, Candida albicans, and more; food processing bacteria including E. coli, Listeria, and Salmonella; and organisms of veterinarian concern such as parvovirus, distemper and Bordetella. PCT Corp.'s proprietary equipment product line includes: 1) PCT Hydrolyte^® Generators, 2) PCT Annihilyzer^® Infection Control Systems, and 3) SurvivaLyte^® equipment. The Hydrolyte^® Generators produce large volumes of electrolyzed water for the agriculture, oil and gas, and fluid distribution markets. The Annihilyzer^® Infection Control Systems, which boast patented RFID material tracking technology, Electrostatic Smart Applicators, on-site automated ECA generators, and Green Seal standards containing stringent performance, health, and sustainability criteria, are ideal for hospitals and healthcare facilities. The SurvivaLyte^® unit is a portable, small volume generator with applications such as disaster recovery, emergency preparedness, remote on-site needs, farm and ranch, and personal use. PCT Corp's unique patented systems and human-safe products provide next-generation cleaning, sanitizing, disinfecting and decontaminating fluid solutions to the ever-present problems of microbial infection and infestation.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward-looking statements."

Such statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Such statements involve risks and uncertainties, including but not limited to: any implied or perceived benefits resulting from the master services agreement; continued positive results relating to cleaning and disinfecting treatment; actual sales revenue to be derived from the agreement; PCTL's and its subsidiaries business prospects; PCTL’s ability to raise sufficient funds to satisfy its working capital requirements; the ability of PCTL to execute its business plan; benefits of the Annihilyzer^® systems and fluids; any other effects resulting from the information disclosed above; risks and effects of legal and administrative proceedings and government regulation; future financial and operational results; competition; general economic conditions; and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated.

Important factors that could cause actual results to differ materially from the forward-looking statements PCTL makes in this press release include market conditions and those set forth in reports or documents it files from time to time with the SEC. PCTL undertakes no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

1. How HAIs lead to direct, indirect and unintended hospital costs, , May 26, 2015

Contact:

Gary Grieco, CEO

(843) 390-7900 Office

(843) 390-2347 Fax